<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01134666</url>
  </required_header>
  <id_info>
    <org_study_id>EMR 062202-517</org_study_id>
    <nct_id>NCT01134666</nct_id>
  </id_info>
  <brief_title>An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer</brief_title>
  <official_title>An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Ltd., India</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck KGaA</source>
  <brief_summary>
    <textblock>
      This is an open-label, non-randomized, prospective, multicentric, Phase IV study evaluating
      FOLFIRI/ FOLFOX plus cetuximab in the first-line therapy of subjects with KRAS wild-type
      metastatic CRC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cetuximab, a chimeric immunoglobulin G1 (IgG1) monoclonal antibody, has been found to
      potentiate the effects of chemotherapy and radiotherapy in experimental systems. The findings
      from clinical trials suggest a favorable risk-benefit ratio of the combination of irinotecan
      or oxaliplatin, infusional 5-FU/FA and biweekly cetuximab, and support the current study to
      demonstrate the therapeutic value of the biweekly cetuximab regimen as a combination partner
      for those regimens in subjects with KRAS wild-type mCRC in the first-line setting. The
      purpose of this study is to generate post marketing surveillance (PMS) data for cetuximab in
      first-line mCRC, which is mandated by the Licensing Authorities.

      This is an open-label, non-randomized, prospective, multicentric Phase IV study evaluating
      FOLFIRI/ FOLFOX plus cetuximab in the first-line therapy of subjects with KRAS wild-type
      metastatic CRC. The study plans to enroll 100 subjects with KRAS wild type CRC at 20 centres
      across India. Tumour status, physical and laboratory examinations will be performed during
      the baseline visit. Subjects will be administered FOLFIRI/ FOLFOX and cetuximab according to
      the clinical condition in the following treatment visits. Regular safety assessments and all
      adverse events (AEs) will be documented throughout and until the end-of-study visit. The
      outcome of AEs ongoing at the final tumour assessment visit will be followed up at the
      end-of-study visit (If possible, 6 weeks after the last administration of study medication
      but before second-line anticancer treatment, and not earlier than 30 days after the end of
      study treatment). Skin toxicity present at the end-of-study visit will be followed up until
      outcome is known.

      OBJECTIVES

      Primary Objective:

        -  To evaluate the safety and tolerability of Cetuximab in combination with standard
           chemotherapy such as FOLFOX or FOLFIRI as first-line therapy of patients with KRAS
           wild-type metastatic colorectal cancer.

      Secondary Objective:

        -  To evaluate the efficacy of Cetuximab in combination with standard chemotherapy as
           first-line therapy of patients with KRAS wild-type metastatic colorectal cancer.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was discontinued due to slow recruitment and subjects not completing follow up
    period.
  </why_stopped>
  <start_date type="Actual">November 30, 2009</start_date>
  <completion_date type="Actual">August 5, 2014</completion_date>
  <primary_completion_date type="Actual">July 31, 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability evaluated based on the incidence and severity of AEs.</measure>
    <time_frame>From baseline to follow-up visit for any ongoing AEs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Baseline to End-of-Study Visit</time_frame>
    <description>Disease Control Rate (DCR), Progression Free Survival (PFS)and Overall Survival (OS)</description>
  </secondary_outcome>
  <enrollment type="Actual">165</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>FOLFOX Oxaliplatin 100 mg/ m2 day 1 Folinic Acid 400 mg/m² (racemic) or 200 mg/m² (L-form) day 1 5- FU 400 mg/m² bolus on day 1 followed by a 46-hour continuous infusion of 2,400 mg/m² day 1 FOLFIRI Irinotecan 180 mg/ m2 day 1 Folinic Acid 400 mg/m² (racemic) or 200 mg/m² (L-form) day 1 5- FU 400 mg/m² bolus on day 1 followed by a 46-hour continuous infusion of 2,400 mg/m² day 1 CETUXIMAB Cetuximab administered at loading dose of 400 mg/m2/week over 120 min followed by maintenance dose of 250 mg/m2/ week over 60 min, till disease progression or dose limiting toxicity</description>
    <other_name>Erbitux</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood and Tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with KRAS wild-type CRC receiving FOLFOX/FOLFIRI and cetuximab in India.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with histologically confirmed, adenocarcinoma of the colon or rectum (mCRC)

          -  Subjects with KRAS wild-type status of tumour tissue

          -  Chemotherapy naïve subjects

          -  Subject who have signed written informed consent (as per institutional protocol)

        Exclusion Criteria:

          -  As per summary of product characteristics of cetuximab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajiv Rana, MD</last_name>
    <role>Study Director</role>
    <affiliation>Merck Ltd., India</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indo- American Cancer Institute &amp; Research Centre</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NVS Ramakrishna's Clinic</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500063</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Nikhil's Clinic</name>
      <address>
        <city>Secunderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500025</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nikhil Gharyalpatil's Clinic</name>
      <address>
        <city>Secunderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500025</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ravi Kumar's Clinic</name>
      <address>
        <city>Hyderabad</city>
        <state>Andrapradesh</state>
        <zip>500001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ambaa Hospitals</name>
      <address>
        <city>Hyderabad</city>
        <state>Andrapradesh</state>
        <zip>500008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swarna Sai Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Andrapradesh</state>
        <zip>500059</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manipal Centre For Clinical Research</name>
      <address>
        <city>Mangalore</city>
        <state>Bangalore</state>
        <zip>575 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College Calicut</name>
      <address>
        <city>Kerala</city>
        <state>Calicut</state>
        <zip>673016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemato Oncology Clinic</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kattimani Oncology Clinic</name>
      <address>
        <city>Hubli</city>
        <state>Karnataka</state>
        <zip>580020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKIMS</name>
      <address>
        <city>Srinagar</city>
        <state>Kashmir</state>
        <zip>190001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. K. I. M. S.</name>
      <address>
        <city>Srinagar</city>
        <state>Kashmir</state>
        <zip>190010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. T. P. Sahoo's Clinic</name>
      <address>
        <city>Bhopal</city>
        <state>Madhya Pradesh</state>
        <zip>462001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BND Onco Centre</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joy Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400071</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruby Hall Clinic</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grace Nursing Home</name>
      <address>
        <city>Aizwal</city>
        <state>Mizoram</state>
        <zip>796 009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lilavati Hospital</name>
      <address>
        <city>Bandra</city>
        <state>Mumbai</state>
        <zip>400050</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.L.Raheja Hospital</name>
      <address>
        <city>Mahim</city>
        <state>Mumbai</state>
        <zip>400016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Cancer Institute</name>
      <address>
        <city>Delhi</city>
        <state>New Delhi</state>
        <zip>110044</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rajiv Gandhi Cancer Institute &amp; Research</name>
      <address>
        <city>Delhi</city>
        <state>New Delhi</state>
        <zip>110085</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fortis Escorts Hospital</name>
      <address>
        <city>Amritsar</city>
        <state>Punjab</state>
        <zip>143004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Rajeev Bedi's Clinic</name>
      <address>
        <city>Chandigarh</city>
        <state>Punjab</state>
        <zip>160101</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>D.M.C Hospital</name>
      <address>
        <city>Ludhiana</city>
        <state>Punjab</state>
        <zip>141001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVY Hospital</name>
      <address>
        <city>Mohali</city>
        <state>Punjab</state>
        <zip>160071</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Clinic</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMS Hospital</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhagwan Mahaveer Cancer Hospital</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhagwan Mahaveer Cancer Hospital &amp; Research Centre</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302030</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vyas Cancer Care</name>
      <address>
        <city>Jodhpur</city>
        <state>Rajasthan</state>
        <zip>3420003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TC 14/ 764 Sreemangalam</name>
      <address>
        <city>Trivandrum</city>
        <state>Tamilnadu</state>
        <zip>695011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shati Gopal Hospital</name>
      <address>
        <city>Ghaziabad</city>
        <state>Uttar Pradesh</state>
        <zip>201014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Annapurna Medical and Cancer Relief Society</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chittaranjan National Cancer Institute</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Gleneagles Cancer Hospital</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nothern Railway Central Hospital</name>
      <address>
        <city>Delhi</city>
        <zip>110055</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indraprastha Apollo Hospital</name>
      <address>
        <city>Delhi</city>
        <zip>110076</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanti Mukand Hospital</name>
      <address>
        <city>Delhi</city>
        <zip>110092</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dharamshila Cancer Hospital &amp; Research Centre</name>
      <address>
        <city>Delhi</city>
        <zip>110096</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2010</study_first_submitted>
  <study_first_submitted_qc>May 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2010</study_first_posted>
  <last_update_submitted>June 8, 2017</last_update_submitted>
  <last_update_submitted_qc>June 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal neoplasms</keyword>
  <keyword>Intestinal neoplasms</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>cetuximab</keyword>
  <keyword>Erbitux</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

